Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H8NO3.Na |
Molecular Weight | 201.1545 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC(=O)NC1=CC=C(C=C1)C([O-])=O
InChI
InChIKey=QCTHGBUDZUJILN-UHFFFAOYSA-M
InChI=1S/C9H9NO3.Na/c1-6(11)10-8-4-2-7(3-5-8)9(12)13;/h2-5H,1H3,(H,10,11)(H,12,13);/q;+1/p-1
DescriptionSources: https://www.medicines.org.uk/emc/medicine/27089Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2431857
Sources: https://www.medicines.org.uk/emc/medicine/27089
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/2431857
Acedoben (4-acetamidobenzoic acid) is a benzoic acid derivative and a metabolite of benzocaine. It is a component of immunomodulatory drug inosine pranobex, which is used to treat mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0006955 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2431857 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | IMUNOVIR Approved UseImunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date1983 |
|||
Primary | IMUNOVIR Approved UseImunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date1983 |
|||
Primary | IMUNOVIR Approved UseImunovir tablets are indicated in the management of mucocutaneous infections due to herpes simplex virus (type 1 and/or type II), genital warts as adjunctive therapy to podophyllin or carbon dioxide laser, and subacute sclerosing panencephalitis. Launch Date1983 |
PubMed
Title | Date | PubMed |
---|---|---|
Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. | 1986 Nov |
|
Effects of the butylated hydroxyanisole and butylated hydroxytoluene on the DNA adduct formation and arylamines N-acetyltransferase activity in human colon tumor cells. | 2001 Mar-Apr |
|
Toxicology and carcinogenesis studies of p-nitrotoluene (CAS no. 99-99-0) in F344/N rats and B6C3F(1) mice (feed studies). | 2002 May |
|
PCR and flow cytometric analysis of paclitaxel-inhibited arylamine N-acetyltransferase activity and gene expression in human osteogenic sarcoma cells (U-2 OS). | 2004 Jan-Feb |
|
Simultaneous determination of p-aminobenzoic acid and its metabolites in the urine of volunteers, treated with p-aminobenzoic acid sunscreen formulation. | 2007 Mar 12 |
|
Prognostic value of N-terminal pro-brain natriuretic peptide in elderly people with acute myocardial infarction: prospective observational study. | 2009 May 6 |
|
Coordinated scaling of cortical and cerebellar numbers of neurons. | 2010 |
|
Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes. | 2015 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.medicines.org.uk/emc/medicine/27089
Mucocutaneous herpes simplex: 1 g q.d.s. (4g daily), for 7 -14 days. Genital warts: 1g t.d.s. (3g daily), for 14-28 days as adjunctive therapy to podophyllin or carbon dioxide laser. Subacute sclerosing panencephalitis (SSPE): 50-100mg/kg daily, in divided does every 4 hours.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2431857
Inosine pranobex has been shown to stimulate various indices of metabolic activity of macrophages and monocytes. In vitro exposure to inosine pranobex or to 24-hour supernatants obtained from mononuclear cells pretreated with the drug restored chemotaxis to normal or near normal levels. Incubation with inosine pranobex in vitro stimulated the production of interleukin-l (lymphocyte activating factor) in human monocytes.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DBSALT002366
Created by
admin on Fri Dec 15 15:46:36 GMT 2023 , Edited by admin on Fri Dec 15 15:46:36 GMT 2023
|
PRIMARY | |||
|
23681162
Created by
admin on Fri Dec 15 15:46:36 GMT 2023 , Edited by admin on Fri Dec 15 15:46:36 GMT 2023
|
PRIMARY | |||
|
DTXSID10183550
Created by
admin on Fri Dec 15 15:46:36 GMT 2023 , Edited by admin on Fri Dec 15 15:46:36 GMT 2023
|
PRIMARY | |||
|
IO8823D6X7
Created by
admin on Fri Dec 15 15:46:36 GMT 2023 , Edited by admin on Fri Dec 15 15:46:36 GMT 2023
|
PRIMARY | |||
|
29305-16-6
Created by
admin on Fri Dec 15 15:46:36 GMT 2023 , Edited by admin on Fri Dec 15 15:46:36 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD